Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Discovery of antichagasic inhibitors by high-throughput screening with Trypanosoma cruzi glucokinase.

Mercaldi GF, D'Antonio EL, Aguessi A, Rodriguez A, Cordeiro AT.

Bioorg Med Chem Lett. 2019 Aug 1;29(15):1948-1953. doi: 10.1016/j.bmcl.2019.05.037. Epub 2019 May 20.

PMID:
31133533
2.

Structure-based approach to the identification of a novel group of selective glucosamine analogue inhibitors of Trypanosoma cruzi glucokinase.

D'Antonio EL, Deinema MS, Kearns SP, Frey TA, Tanghe S, Perry K, Roy TA, Gracz HS, Rodriguez A, D'Antonio J.

Mol Biochem Parasitol. 2015 Dec;204(2):64-76. doi: 10.1016/j.molbiopara.2015.12.004. Epub 2016 Jan 14.

3.

The crystal structure of Trypanosoma cruzi glucokinase reveals features determining oligomerization and anomer specificity of hexose-phosphorylating enzymes.

Cordeiro AT, Cáceres AJ, Vertommen D, Concepción JL, Michels PA, Versées W.

J Mol Biol. 2007 Oct 5;372(5):1215-26. Epub 2007 Jul 26.

PMID:
17761195
4.

The crystal structure of glucokinase from Leishmania braziliensis.

Buechner GS, Millington ME, Perry K, D'Antonio EL.

Mol Biochem Parasitol. 2019 Jan;227:47-52. doi: 10.1016/j.molbiopara.2018.12.002. Epub 2018 Dec 17.

PMID:
30571993
5.

Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery.

Ekins S, de Siqueira-Neto JL, McCall LI, Sarker M, Yadav M, Ponder EL, Kallel EA, Kellar D, Chen S, Arkin M, Bunin BA, McKerrow JH, Talcott C.

PLoS Negl Trop Dis. 2015 Jun 26;9(6):e0003878. doi: 10.1371/journal.pntd.0003878. eCollection 2015.

6.

Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.

Engel JC, Ang KK, Chen S, Arkin MR, McKerrow JH, Doyle PS.

Antimicrob Agents Chemother. 2010 Aug;54(8):3326-34. doi: 10.1128/AAC.01777-09. Epub 2010 Jun 14.

7.

Molecular and biochemical characterization of novel glucokinases from Trypanosoma cruzi and Leishmania spp.

Cáceres AJ, Quiñones W, Gualdrón M, Cordeiro A, Avilán L, Michels PA, Concepción JL.

Mol Biochem Parasitol. 2007 Dec;156(2):235-45. Epub 2007 Aug 26.

PMID:
17904661
8.

Discovery of new uncompetitive inhibitors of glucose-6-phosphate dehydrogenase.

Mercaldi GF, Ranzani AT, Cordeiro AT.

J Biomol Screen. 2014 Dec;19(10):1362-71. doi: 10.1177/1087057114546896. Epub 2014 Aug 13.

PMID:
25121555
9.

Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.

Hargrove TY, Wawrzak Z, Alexander PW, Chaplin JH, Keenan M, Charman SA, Perez CJ, Waterman MR, Chatelain E, Lepesheva GI.

J Biol Chem. 2013 Nov 1;288(44):31602-15. doi: 10.1074/jbc.M113.497990. Epub 2013 Sep 18.

10.

Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening.

Melo-Filho CC, Braga RC, Muratov EN, Franco CH, Moraes CB, Freitas-Junior LH, Andrade CH.

Eur J Med Chem. 2019 Feb 1;163:649-659. doi: 10.1016/j.ejmech.2018.11.062. Epub 2018 Nov 29.

PMID:
30562700
11.

Activity in vivo of anti-Trypanosoma cruzi compounds selected from a high throughput screening.

Andriani G, Chessler AD, Courtemanche G, Burleigh BA, Rodriguez A.

PLoS Negl Trop Dis. 2011 Aug;5(8):e1298. doi: 10.1371/journal.pntd.0001298. Epub 2011 Aug 30.

12.

Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit.

Chen CK, Doyle PS, Yermalitskaya LV, Mackey ZB, Ang KK, McKerrow JH, Podust LM.

PLoS Negl Trop Dis. 2009;3(2):e372. doi: 10.1371/journal.pntd.0000372. Epub 2009 Feb 3.

13.

Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease.

Riley J, Brand S, Voice M, Caballero I, Calvo D, Read KD.

PLoS Negl Trop Dis. 2015 Sep 22;9(9):e0004014. doi: 10.1371/journal.pntd.0004014. eCollection 2015 Sep.

14.

Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening.

Bettiol E, Samanovic M, Murkin AS, Raper J, Buckner F, Rodriguez A.

PLoS Negl Trop Dis. 2009;3(2):e384. doi: 10.1371/journal.pntd.0000384. Epub 2009 Feb 24.

15.

Subcellular localization of glycolytic enzymes and characterization of intermediary metabolism of Trypanosoma rangeli.

Rondón-Mercado R, Acosta H, Cáceres AJ, Quiñones W, Concepción JL.

Mol Biochem Parasitol. 2017 Sep;216:21-29. doi: 10.1016/j.molbiopara.2017.06.007. Epub 2017 Jun 20.

PMID:
28645481
16.

In vitro drug susceptibility of two strains of the wildlife trypanosome, Trypanosoma copemani: A comparison with Trypanosoma cruzi.

Botero A, Keatley S, Peacock C, Thompson RC.

Int J Parasitol Drugs Drug Resist. 2017 Apr;7(1):34-41. doi: 10.1016/j.ijpddr.2016.12.004. Epub 2016 Dec 23.

17.

Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line.

Alonso-Padilla J, Cotillo I, Presa JL, Cantizani J, Peña I, Bardera AI, Martín JJ, Rodriguez A.

PLoS Negl Trop Dis. 2015 Jan 23;9(1):e0003493. doi: 10.1371/journal.pntd.0003493. eCollection 2015 Jan.

18.

Identification of Specific Inhibitors of Trypanosoma cruzi Malic Enzyme Isoforms by Target-Based HTS.

Ranzani AT, Nowicki C, Wilkinson SR, Cordeiro AT.

SLAS Discov. 2017 Apr 1:2472555217706649. doi: 10.1177/2472555217706649. [Epub ahead of print]

PMID:
28459632
19.

The structure of a Trypanosoma cruzi glucose-6-phosphate dehydrogenase reveals differences from the mammalian enzyme.

Mercaldi GF, Dawson A, Hunter WN, Cordeiro AT.

FEBS Lett. 2016 Aug;590(16):2776-86. doi: 10.1002/1873-3468.12276. Epub 2016 Jul 19.

20.

Antiprotozoal drug nitazoxanide enhances parasitemia, tissue lesions and mortality caused by Trypanosoma cruzi in murine model.

Valle-Reyes JS, Melnikov V, Dobrovinskaya O, Rodriguez-Hernández A, Wookee-Zea C, Pimientel-Rodrigez V, Rueda-Valdovinos G, Delgado-Enciso I, López-Lemus UA, Espinoza-Gómez F.

Exp Parasitol. 2017 Jan;172:44-50. doi: 10.1016/j.exppara.2016.12.013. Epub 2016 Dec 21.

PMID:
28011170

Supplemental Content

Support Center